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Introduction
Opium, a highly addictive substance obtained from the 
unripe seedpod of the poppy plant, is illicitly consumed 
by millions of people around the world, particularly in 
central Asian countries.1 Freshly taken from the poppy 
plant, opium contains alkaloids (e.g., morphine, codeine, 
and thebaine) and non-alkaloids (e.g., water, sugars, fat, 
and meconic acid). It is often minimally processed by 
heating, boiling, and drying, and variably adulterated with 
some chemicals (e.g., lead or chromium) before it reaches 
consumers. In the minimally processed form, opium may 
be consumed as raw opium (teriak), opium sap (shireh), 
or opium dross (sukhteh).2 These forms of opium may be 
ingested or smoked. Therefore, similar to tobacco, opium 
is a complex substance with many chemicals. 
Case-control and cohort studies, conducted mainly 
within the past two decades, have provided substantial 
evidence that opium use could increase the risk of 
overall death, cardiovascular mortality,3 and cancer 
mortality.4,5 Opium use has been found to be associated 
with higher risk of cancers of the larynx,4-7 bladder,8-10 
lung,10-12 pharynx,6,7,13,14 stomach,10,15,16 esophagus,10,17-20 
pancreas10,21,22 and colon and rectum.23,24 Using data from 
these studies, complemented by mechanistic studies, the 
International Agency for Research on Cancer (IARC) 
recently classified opium use a Group 1 carcinogen, i.e. 
carcinogenic in humans.25,26 
The IARC Working Group concluded that opium use 
causes cancers of the larynx, lung, and bladder. However, 
there remain substantial knowledge gaps for the association 
of opium use and cancer. For example, elucidating the 
magnitude of the association for these cancers and studying 
the interaction of opium use with tobacco smoking for these 
cancers need further investigation. Despite the availability 
of some credible data, it is unclear whether opium causes 
cancers of the esophagus, stomach, or pancreas. Data for 
some cancers, most notably those of colon and rectum, 
are contradictory.10,24 While epidemiologic findings so far 
suggest that consumption of opium in its various forms 
(teriak, shireh and sukhteh) and major exposure routes 
(ingestion and smoking) would be carcinogenic, there is 
a clear need for further data to support these findings. To 
advance the science in this field, we initiated the Iranian 
Opium and Cancer (IROPICAN) Study in 2012, to 
evaluate the association of opium exposure with risk of 
cancers of the head and neck, lung, bladder, and colon 
and rectum. 
We aimed to advance the field by planning studies that 
had a substantially larger sample size than any studies 
before, and to collect detailed data on opium use needed 
for dose-response analyses, controlling for potential 
confounders, and evaluation of possible reverse causality.27 
The findings for head and neck cancer are already 
published which showed odds ratio (OR) (3.76, 95% CI: 
2.96–4.79) for regular opium use6 and contributed to the 
recent IARC Working Group conclusions, particularly 
for laryngeal and pharyngeal cancer evaluation. The data 
for the remaining cancer sites are being analyzed. While 
the IROPICAN study is primarily focused on opium 
use, the researchers have collected substantial data on 
other important exposures (e.g., waterpipe use) and 
collected biological samples that can be used for a host of 
epidemiological studies. Therefore, a clear and thorough 
description of methods and available data will be of 
interest for the readers of future studies. 
The objective of this paper is to introduce the 
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Background: The International Agency for Research on Cancer (IARC) recently classified opium use as a Group 1 carcinogen. 
However, much remains to be studied on the relation between opium and cancer. We designed the Iranian Opium and Cancer 
(IROPICAN) study to further investigate the association of opium use and cancers of the head and neck, bladder, lung, and colon 
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Methods: The IROPICAN is a multi-center case-control study conducted in 10 provinces of Iran. The cases were all histologically 
confirmed and the controls were selected from hospital visitors who were free of cancer, were not family members or friends of 
the cancer patients, and were visiting the hospital for reasons other than their own ailment. The questionnaires included detailed 
questions on opium use (including age at initiation, duration, frequency, typical amount, and route), and potential confounders, 
such as tobacco use (e.g., cigarettes, nass and water-pipe), and dietary factors. Biological samples, including blood and saliva, 
were also collected. 
Results: The validation and pilot phases showed reasonably good validity, with sensitivities of 70% and 69% for the cases and 
controls, respectively, in reporting opium use. The results also showed excellent reliability, with intra-class correlation coefficients 
of 0.96 for ever opium use and 0.88 (95% CI: 0.80, 0.92) for regular opium use. In the main phase, we recruited 3299 cancer 
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IROPICAN study, including the study setting, design of 
the questionnaires, validity and reliability of the responses, 
biological samples collected during the study, the rationale 
for selection of controls, and the potential for in-depth 
evaluation of cancer risk factors using the material 
collected in these studies. 
Materials and Methods
Study Setting
The IROPICAN case-control study was conducted in Iran, 
a country with a high consumption rate of opium1 that has 
a strong infrastructure for conducting large-scale studies. 
It was a multi-center study, conducted in 10 provinces 
that were estimated to have medium to high opium use,28 
namely Tehran, Kerman, Fars, Golestan, Khorasan-Razavi, 
Kermanshah, Mazandaran, Bushehr, Hormozgan, and 
Sistan-Baluchestan (Figure 1), to evaluate the association 
between opium consumption and risk of cancers of the 
head and neck, lung, bladder, and colon and rectum. 
The regions were selected based on prevalence of opium 
use and availability of cancer care centers for recruiting 
patients and contols. Of these, Tehran, Kerman, Fars, and 
Golestan were the first provices to join the study in 2014 
to 2015. Later, Kemanshah, Mazandaran, and Khorasan-
Razavi joined in 2017 and 2018, followed by Hormozgan, 
Sistan-Blouchestan, and Bushehr in 2018 to 2020. 
Questionnaires
We developed a detailed questionnaire and administered 
it to all study participants. This questionnaire was adapted 
from the Golestan Cohort Study,29 because it had detailed 
data on opium use, had been tested extensively in the 
field (in the cohort and several case-control studies), was 
the basis of many publications, and could be eventually 
Figure 1. Distribution of the Iran Opium and Cancer (IROPICAN) study sites 
in different provinces of Iran.
used for combined analyses of data. The IROPICAN 
questionnaire include detailed questions on opium use, 
including types of opium used (e.g. teriak, shireh, sukhteh), 
routes of opium use (smoking versus ingestion), age of 
initiating and stopping opium use, and frequency and 
amount of opium use. The questionnaire also include 
extensive data on covariates, such as: demographic and 
socioeconomic factors (e.g. age, ethnicity, rural/urban 
status, education, occupational history, various amenities 
owned; physical activity (using the international physical 
activity questionnaire, IPAQ30); information on various 
aspects of health (oral health, female reproductive history, 
history of various diseases, personal and family history of 
cancer); life-long consumption of tobacco in the forms 
of cigarettes, water-pipe, pipe, naswar, and chopogh 
(a special pipe); history of alcohol consumption; and 
history of opioid use (e.g. diphenoxylate, methadone, 
morphine, codeine); history of other illicit drug use (e.g. 
heroin, heroin crack, hashish, tramadol, methadone). The 
crack used in Iran is heroin-based and different from the 
cocaine-based34 crack used in Western countries. We used 
a validated and reproducible 130-item food frequency 
questionnaire similar to that used in the Persian Cohort 
Study, a large study aiming to recruit 150 000 Iranians 
aged 35–70 years from 18 regions of Iran.31
Physical Examination and Biological Sample Collection
All prospective study participants underwent physical 
examination using a standard protocol and performed by 
trained personnel. Weight was measured using a portable 
non-digital weight scale (Fazeni), height with a height 
scale (Seca), and blood pressure was measured with a 
digital scale (Haalar).32,33 
Blood samples were collected to study the presence of 
different opium adulterants34 and their associations with 
selected cancers. We collected 12 mL of venous whole blood 
for each cancer case and control. From this sample, 6 mL 
is kept in a vacutainer tube with EDTA anticoagulant for 
DNA extraction; 3 mL is stored for RNA extraction, and 3 
mL is stored in a vacutainer tube without anticoagulant for 
serum extraction. One drop of blood is stored in a DNA 
banking card. Oral saliva from head and neck cancer cases 
and their controls is collected for assessing the prevalence 
of human papillomavirus (HPV) and its serotypes. 
Blood and saliva samples were stored at minus 20 degrees 
Celsius in each province and shipped to the main center 
every month (maximum two months after collection) for 
storage at minus 80 degrees Celsius. DNA extraction was 
done using the salting-out method at the Cancer Research 
Center (CRC), Cancer Institute of Iran; extracted DNAs 
were stored at minus 20 degrees Celsius. These biological 
samples will be used for several other projects in the future 
including potential genome-wide association studies in 
international consortia.
 Arch Iran Med, Volume 24, Issue 3, March 2021                                                        170
Hadji et al 
Interviewer Training and Project Management
Interviewers with a bachelor’s or master’s degree in public 
health or biology were trained intensively to use a standard 
protocol, to carry out standardized interviews, and to 
collect samples for the study. One experienced researcher 
in each province was responsible for the management 
of field-work and data collection. In addition, a central 
coordinator based in the main center (Cancer Research 
Center in Tehran University) tracked all implemented 
work daily, and made a visit to each center twice a year to 
supervisor the operations. Each center regularly reported 
the number of cases and controls recruited.
Choosing the Most Appropriate Control Group Using a 
Validation Study
Self-reported opium use in the Golesan Cohort Study was 
strongly correlated with urine morphine metabolites in 
a sample of 130 study cohort participants35; using urine 
codeine or morphine as the gold standard for use of opium, 
self-report had a sensitivity of 0.93 and a specificity of 
0.89. However, the validity of this questionnaire outside 
the Golestan Province was unclear. Therefore, in June-
July 2016, a validation study was conducted in four 
provinces that were first selected as study sites – Kerman, 
Fars, Golestan, and Tehran – to estimate the magnitude 
of underreporting and to determine the best potential 
control group. 
The two potential control choices were: 1) hospitalized 
non-cancer patients (178 men); and 2) healthy hospital 
visitors who were companions of patients with chronic 
diseases (186 men). The prevalence of self-reported 
regular opioid use, defined as using at least once a week 
for six months, was 36% (95% confidence interval: 
28%, 43%) in hospitalized patients versus 19% (95% 
CI: 13%, 25%) in healthy individuals.36 Compared to a 
gold standard of using urine rapid drug screen and thin 
layer chromatography, self-reported use had a sensitivity of 
77% in hospitalized patients and 69% in healthy visitors 
(P = 0.4).36 After correction for sensitivity, the frequency 
of regular opioid use (primarily opium use) was 47% 
and 28% in hospitalized patients and healthy visitors 
individuals, respectively. Because 47% was a substantial 
overestimation of the estimated prevalence of use in the 
population, and that sensitivity of self-reported use was 
comparable in the two control groups, we opted for the 
healthy visitor controls in the IROPICAN Study. 
Validation of Self-reported Opium Use in Cases
We studied the sensitivity of self-reported opium use in a 
study of 100 cancer patients (with various types of cancer) 
who were slated for surgery in the Cancer Institute of 
Tehran University of Medical Sciences. We recruited only 
men, to make the results comparable with the validation 
study in controls, with mean age of 61.5 (standard 
deviation, SD: 16.3) years. Most cancer patients had 
Table 1. Intra-class Correlation (ICC) and 95% Confidence Interval (CI) for 
Questions on Opium, Other Drugs, Tobacco and Alcohol Use in the Iranian 
Opium and Cancer (IROPICAN) Multi-center Case-Control Study, 2015–2020
Variables ICC 95% CI
Ever cigarette use 0.96 (0.94, 0.97)
Regular cigarette use 0.95 (0.91, 0.97)
Ever water pipe use 0.88 (0.80, 0.93)
Regular water pipe use 0.99 (0.98,0.99)
Ever chopogh use 0.88 (0.80, 0.93)
Regular chopogh use 0.96 (0.93, 0.98)
Ever opium use 0.96 (0.93, 0.96)
Regular opium use 0.88 (0.80, 0.92)
Ever heroin use 0.95 (0.92, 0.97)
Regular heroin use 0.92 (0.86, 0.95)
Ever hashish use 0.98 (0.96, 0.98)
Regular hashish use 0.91 (0.85, 0.95)
Ever codeine use 0.89 (0.81, 0.93)
Regular codeine use 0.94 (0.89, 0.96)
Ever tramadol use 0.90 (0.82, 0.94)
Regular tramadol use 0.84 (0.72, 0.91)
Ever diphenoxylate use 0.95 (0.92, 0.97)
Regular diphenoxylate use 0.84 (0.71, 0.91)
Ever methadone use 0.94 (0.90, 0.96)
Regular methadone use 0.97 (0.96, 0.98)
Ever alcohol use 0.98 (0.96, 0.98)
Regular alcohol use 0.99 (0.98, 0.99)
Type of opium 0.97 (0.95, 0.98)
Route of opium use 0.78 (0.63, 0.90)
used opioids to alleviate pain; therefore, urine test results 
could not be used to validate responses. Instead, we used 
patient’s response to the anesthesiologist’s questions as gold 
standard; anesthesiologists routinely ask these questions 
before each surgery to prevent withdrawal syndrome. 
Sensitivity of self-reported opium use was 69.6%. 
Reliability Study 
The Golestan Cohort Study questionnaire had shown 
excellent reliability for ever opium use report, with a kappa 
of 0.96.35 To confirm again, we assessed the reliability of 
the questions of drug, tobacco, and alcohol use in 57 
patients (47 men and 10 women) who were referred to an 
addiction control center. We used a test-retest approach, 
with the second administration done two weeks after 
the first. The intraclass correlation coefficient (ICC) of 
lifetime opium use was 0.96, and the ICC for regular use 
of opium was 0.88 (95% CI, 0.80, 0.92). The ICC was 
0.78 (95% CI: 0.63, 0.90) for method of opium use and 
0.97 (95% CI: 0.95, 0.98) for opium type (Table 1).
Pilot Study 
In the pilot study conducted in January-April 2017, we 
recruited patients with four types of cancer as the case 
group and healthy visitors as the control group from 
referral cancer care centers and clinics in the four provinces 
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that were initially selected as study sites (Tehran, Shiraz, 
Kerman, and Golestan). The objectives of the pilot study 
were to: (a) determine the feasibility of the case-control 
study; (b) optimize the questionnaires; (c) train partnering 
research institutions for data collection; (d) assess the 
geographic variation of opium use and other opiates 
in different regions of Iran; and (e) optimize biological 
sample collection methods. The pilot study showed that 
conducting the study was feasible. Based on pilot study 
findings, we made minor revisions to the questionnaire, 
primarily focused on questions regarding opium use and 
other drug use. For example, a question about frequency 
of opium use per day/week/month/year was added. The 
other aims of the pilot study were also achieved. Only 
minor changes were made in sample collection and 
methodology when the full project was set up. Partnering 
institutions received the required training. Also, variability 
of the opium consumption was determined. Following a 
successful pilot study, we calculated the required sample 
size and started recruitment of the cases and controls. 
Sample Size Calculation
While it is difficult to accurately estimate the prevalence 
of opium use as an illicit substance37 the use of which 
is also associated with some social stigma,38 the results 
of national surveys and our pilot results suggested that 
a prevalence of approximately 20% among the controls 
was a reasonable assumption. Assuming a prevalence of 
20% of opium use in the Iranian population39,40 living 
in high prevalence regions, 90% power and a two-sided 
significance level of 0.05, we estimated that 250 cases and 
250 controls would be sufficient to detect an odds ratio 
of 2.0. However, we chose to aim at a sample size of 800 
cases for each type of cancer (i.e. 3200 cancer cases overall) 
and 3200 common controls, to allow for various subgroup 
analyses.39,40 Where possible, we exceeded this number. As 
of the date this report, we included 743 lung cancers, 920 
colorectal cancers, 717 bladder cancers, and 919 head and 
neck cancers. 
Case Recruitment
Patients with confirmed histological primary cancers of the 
lung (ICD-10: C33-34), colorectum (C18-21), bladder 
(C67), or squamous cell carcinoma (SCC) of the head 
and neck (i.e., oral cavity (C03-06), larynx (C32) and 
pharynx (C10-C14)) admitted to referral hospitals of the 
universities of medical sciences of 10 provinces (Tehran, 
Kerman, Fars, Golestan, Khorasan-Razavi, Kermanshah, 
Mazandaran, Bushehr, Hormozgan, and Sistan-
Baluchestan), were recruited as cases. We only included 
newly diagnosed resident cancer cases, defined as those 
who had received a diagnosis within one year prior to the 
date of interview and who had resided at least two years 
in the study region. Other inclusion criteria were being 
of Iranian nationality, ability to speak and understand the 
Farsi language, ability to participate in an interview taking 
about 80 minutes, and being in the age range of 30 to 
75 years. Patients with metastatic cancers, second primary 
cancers, and those without a confirmed pathology report 
were excluded. Pregnant and nursing women were also 
excluded from the study. 
Control Recruitment
The control study participants (hospital visitors) were 
enrolled concurrently with the cases. The controls (who 
had to be free of cancer) were chosen from the relatives 
or friends of patients from non-oncology wards, or others 
who visited the hospital for reasons other than receiving 
treatment. Choosing healthy visitors was a conclusion that 
we had reached during the validation studies (see above). 
Another rationale for this choice of controls was that we 
aimed at excluding those who were ill (hence, more likely 
than the general population to use opium) and family 
members or friends of patients with cancer (who are likely 
to share many habits, including opium use) with the cases. 
Other inclusion criteria were similar to those of cases, i.e., 
being of Iranian nationality, ability to speak and understand 
the Farsi (Persian) language, ability to participate in an 
interview taking about 80 minutes, and being in the age 
range of 30 to 75 years. We aimed at enrolling controls 
who were frequency-matched to the cases for gender, age 
(five year intervals), and place of residence (by province 
and capital city/non-capital city). 
Data Processing and Exposure Assessment 
Ever-use of opium was defined as using opium at least 
once during lifetime and regular opium use was defined as 
using opium at least once a week for at least six consecutive 
months. The cumulative amount of lifetime opium use 
was defined as the amount of opium use (grams per day) 
multiplied by days of opium use during lifetime. 
We calculated pack-years, starting age and stopping age 
of cigarette use to be used as the main measure of exposure 
to cigarette smoking. Other types of tobacco used in the 
area are water pipe, pipe, and chopogh (a special type of 
pipe with a long tube).41 For water pipe, the head-year unit 
was calculated for cumulative use.45 For estimation of use 
of alcohol, one standardized unit was defined as follows: 
340 cc of beer; 150 cc of wine or champagne; or 40 cc of 
vodka, fortified wine or whisky. We provided an album 
containing pictures of standard units such as pilsner, glass, 
cocktail and tablespoon to participants to report their 
portion size according to the standardized units. 
We created a composite variable for socioeconomic 
status using a host of variables, as described elsewhere.42 
Results
Overall, 3299 cancer patients (743 with lung cancer, 920 
with colorectal cancer, 717 with bladder cancer and 919 
with head or neck cancer) and 3477 controls participated 
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in the main study. The response rate was 99% (3299 out 
of 3314) among the cases who were capable to participate 
and 89% (3477 out of 3925) among the controls. 
Non-participants
Only 1% of the invited cases and 11% of the invited controls 
chose not to participate in the study. The main stated 
reasons for non-participation were sickness and lethargy 
among cancer patients (93% of the non-participants) and 
lack of time or unwillingness to donate a biological sample 
among controls (83% of the non-participants). Among 
the 15 cases who refused to participate, the mean age 
was 58.8 (SD 11.2) years and 66% were males. Among 
controls who refused to participate, the mean age was 58.3 
(SD 10.9) years and 71% were males. 
Demographic and Geographic Characteristics of the 
Participants
Table 2 shows the demographic characteristics and 
geographic distribution of the study participants by case 
status. The mean age on the interview date was 59.9 (SD 
11.9) years for cases and 57.3 (SD 11.6) years for controls. 
Opium Use
In all, 39.8% of cases and 17.5% of controls reported ever 
use of opium. Patients may start using opium to alleviate 
their pain – a prodromal symptom of subsequently 
diagnosed cancer. Opium’s alkaloid constituents, in 
addition to having narcotic effects, may be used for 
medicinal purposes. For example, morphine has strong 
analgesic effects and may be used to alleviate pain in cancer 
patients, or codeine may be used to suppress cough.43,44 
If cases and controls who started using opium less than 
3 years before their interview date were classified as non-
users, 35.1% of cases and 13.0% of controls were classified 
as opium users (Table 3). 
The median of lifetime use of opium among users 
were 0.9 (25th and 75th percentiles 0.3 and 3.0) gram per 
day among cases and 0.4 (0.1, 2.0) gram per day among 
controls. 
The types of opium consumed differed among opium 
users: 28.0% of cases and 11.8% of controls used teriak 
(Table 3). The most common opium consumption method 
was smoking alone (21.4% of cases, 10.9% of controls).
Tobacco Use
The prevalence of cigarette ever use was 51.4% and 33.4% 
among cases and controls, respectively. The proportion of 
regular cigarette smokers was 48.4% in cases and 28.1% in 
controls. The prevalence of regular water-pipe use among 
cases and controls was 9.1% and 7.5%, respectively. The 
prevalence of regularly chewing nass was 1.7 among cases 
and 0.8 among controls (Table 3).
Biological Samples
Biological samples including whole blood, serum, plasma, 
Table 2. Demographic Characteristics of Cases and Controls Enrolled in the Multi-center Case-Control Study of Opium and Cancer (IROPICAN Study), 2015-
2020, by Cancer Site
Variable
Cases, Site No. (%)
Controls, No. (%)
Lung Colorectal Bladder Head and Neck
Total 743 (100) 920 (100) 717 (100) 919 (100) 3477 (100)
Age
<30 2 (0.3) 7 (0.8) 3 (0.4) 9 (1.0) 21 (0.6)
30–39 22 (3.0) 60 (6.5) 11 (1.5) 55 (6.0) 236 (6.8)
40–49 91 (12.3) 133 (14.5) 50 (7.0) 145 (15.8) 559 (16.1)
50–59 231 (31.1) 258 (28.0) 181 (25.2) 277 (30.1) 1070 (30.8)
60–69 257 (34.6) 274 (29.8) 267 (37.2) 295 (32.1) 1092 (31.4)
>70 138 (18.6) 187 (203) 205 (28.6) 138 (15.0) 499 (14.4)
Missing 2 (0.3) 1 (0.1) - - -
Gender
Female 181 (24.4) 387 (41.1) 93 (13.0) 232 (25.2) 1077 (31.0)
Male 562 (75.6) 533 (57.9) 624 (87.0) 687 (74.8) 2400 (69.0)
Province
Tehran 148(19.9) 170 (18.5) 139 (19.4) 163 (17.7) 816 (23.5)
Fars 233 (31.4) 265 (28.8) 166 (23.2) 379 (41.2) 943 (27.1)
Kerman 128 (17.2) 112 (12.2) 150 (20.9) 160 (17.4) 525 (15.1)
Golestan 64 (8.6) 156 (17) 46 (6.4) 46 (5.0) 374 (10.8)
Mazandaran 36 (4.9) 59 (6.4) 24 (3.4) 17 (1.9) 136 (3.9)
Kermanshah 42 (5.7) 71 (7.7) 52 (7.3) 37 (4.0) 251 (7.2)
Khorasan-Razavi 17 (2.3) 87 (9.5) 30 (4.2) 44 (4.8) 170 (4.9)
Bushehr 38 (5.1) * 56 (7.8) ** 84 (2.4)
Hormozgan 20 (2.3) * 27 (3.8) 37 (4.0) 78 (1.9)
Sistan-Balouchestan 17 (2.3) * 27 (3.8) 36 (3.9) 100 (2.9)
*Colorectal cancer cases were not enrolled in Bushehr, Hormozgan, and Sistan-Baluchestan.
**Head and neck cancer were not enrolled in Bushehr.
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extracted DNA for 2441 cases and 2768 controls, and 
saliva sample for 657 head and neck cancer cases, and 677 
controls are available. 
Discussion
The IROPICAN was designed and tested in various phases 
to serve as a high-quality study to evaluate the causal 
association of opium with various cancers. The results of 
the validation and pilot phases guided the investigators to 
choose the best potential control group, and to optimize 
the questionnaire, data collection, and biological sample 
collection methods. They also showed that the main study 
was feasible. The response rate was high in both cases and 
controls. Matching of controls for age, gender, province, 
and place of residence was feasible. However, the matching 
was not perfect, as the controls were slightly younger than 
the cases and they were more likely to be from Tehran and 
Fars provinces (Figure 2), two active centers that joined 
the study very early on. 
The IROPICAN study has several advantages in 
evaluating the association of opium and cancers. This 
study has detailed information on opium use, including 
age of initiation; typical amount, frequency, duration of 
use; and types and routes of opium use. It also has data on 
potential important confounders, such as age, sex, tobacco 
use, and socioeconomic status. Since we have detailed data 
on amount of use over time, we will be able to examine 
dose-response associations. Reverse causality can be 
addressed in this study by removing those who initiated 
opium use within the three years prior to the interview. 
This is important, as some people with cancer may use 
opium to alleviate their cancer-related pain.22 Indeed, 
the IROPICAN Study has already contributed to the 
evaluation of carcinogenicity of opium use.6,25 
A major challenge in health studies on the effects of opium 
use is gathering reliable data on usage.45 We believe that we 
are using a reasonably accurate method to collect data on 
opium use and other banned substances. We found the 
sensitivity of self-reporting of opium use at 77% and 69% 
among disease-controls and visitor-controls, respectively.36 
The high participation rates and the low denial of drug 
consumption in controls in our study may be due to the 
substantial training and supervision of our interviewers. 
It could also be due to the fact that opium use is quite 
common in Iran. So, although stigmatized, it is not quite 
as big a taboo as in some other countries. Fortunately, the 
sensitivity of reporting was similar in disease-controls and 
visitor-controls. This is in contrast to studies performed 
outside Iran that have reported substantial underreporting 
among controls.46,47 In addition, we found a sensitivity of 
70% for self-reporting opium use among cancer patients, 
which was similar to underreporting of healthy visitor 
controls. Although in case-control studies, information 
bias is typically higher in the controls than in the cases and 
Table 3. Opium and Tobacco Use among the Cases and Controls in the 
Iranian Opium and Cancer (IROPICAN) Multi-center Case-Control Study of 
Opium and Cancer (IROPICAN Study), 2015–2020
Variable Cases, No. (%) Controls, No. (%)
Total 3299 (100) 3477 (100)
Opium use*
Never used 1985 (60.2) 2870 (82.5)
Ever used 1314 (39.8) 607 (17. 5)
Non-regular use 129 (3.9) 139 (4.0)
Regular use 1185 (35.9) 468 (13.5)
Median opium amount
Never used 1985 (60.1) 2870 (82.5)
Non-regular use 129 (3.9) 139 (0.4)
≤0.4 g/d 315 (10.0) 217 (6.2)
>0.4 g/d 870 (26.4) 251 (7.2)
Opium use duration
Never used 1985 (60.1) 2870 (82.5)
Non-regular use 129 (3.9) 139 (4.0)
≤17 years 416 (12.6) 243 (7.0)
>17 years 769 (23.3) 225 (6.5)
Initiation age of opium use
Never used 1985 (60.1) 2870 (82.5)
≤30 years 648 (19.6) 296 (8.5)
>30 years 577 (17.5) 262 (7.5)
Unknown 89 (2.7) 49 (1.4)
Type of opium use
Never used 1985 (60.1) 2870 (82.5)
Non-regular use 129 (3.9) 139 (4.0)
Crude opium (Teriak) 922 (28.0) 411 (11.8)
Opium juice (Shireh) 89 (2.7) 30 (0.9)
Opium dross (Sookhteh) 3 (0.1) 2 (0.06)
More than one type 171 (5.2) 25 (0.7)
Route of opium use 
Never used 1985 (60.1) 2870 (82.5)
Non-regular use 129 (3.9) 139 (4.0)
Smoking 707 (21.4) 380 (10.9)
Ingestion 135 (4.1) 31 (0.9)
Inhalation 21 (0.6) 10 (0.3)
More than one route 318 (9.6) 45 (1.3)
Unknown 4 (0.1) 2 (0.06)
Cigarette use
Never used 1602 (48.6) 2316 (66.6)
Non-regular use 101 (3.1) 184 (5.3)
Regular use 1596 (48.3) 977 (28.1)
Tobacco use
Never used 2932 (88.9) 3177 (91.4)
Regular water pipe use 300 (9.1) 261 (7.5)
Regular chopogh use 2 (0.06) 1 (0.03)
Regular pipe use 9 (0.3) 9 (0.3)
Regular nass 56 (1.7) 29 (0.8)
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leads to differential misclassification, here we found that 
underreporting for opium use was similar in the cancer 
patients and in the controls. Our findings suggest that we 
need to adjust for non-differential bias when we study the 
association between opium use and risk of cancers
In addition to accurate data on opium use, we have 
collected data on a host of other risk factors, such as 
various forms of tobacco use (e.g., cigarettes, water-pipe, 
and nass), which can be used for future epidemiologic 
studies. This wealth of data will also allow us to assess 
possible interaction effects of opium consumption and 
other risk factors of cancers such as water pipe and cigarette 
consumption, and also study the effects of opium in never 
tobacco users. 
From each case and control, a 10 mL sample of 
venous blood was collected for DNA extraction for 
future epidemiological studies to evaluate the association 
between opium use and genetic and molecular markers of 
cancers – a relationship which has not been studied before. 
Additionally, saliva samples were collected from head 
and neck cases and controls to study the prevalence of 
HPV and detect the most prevalent type of HPV among 
head and neck cancer cases in Iran. The data can also be 
combined with opium use, tobacco use, and other data for 
various epidemiologic studies. 
The strengths of this case-control study are its large 
sample size, collection of detailed data on opium use and 
potential confounders, validation of the questionnaires, 
substantial training and supervision of the interviewers, 
high participation rates among cases and controls, careful 
selection of controls, and histologic confirmation of cancer 
diagnoses. Despite our best efforts, however, this study, as 
a case-control study, may still suffer from some biases like 
selection bias and some reporting bias. We did not choose a 
population-based control group because underreporting of 
opium use, as a sensitive matter, in the general population 
may be substantially higher than hospital visitors.48
In conclusions, we were able to successfully design and 
test various steps in conducting this large multi-center 
study. The full study with general questionnaires, food 
frequency questionnaires, and biological samples is by 
far the largest study of association on opium and cancer. 
The findings from this study are expected to make a 
significant contribution to advancing our knowledge on 
carcinogenicity of opium use. The study data can also be 
used to assess the effects of other potential risk factors of 
cancer, such as water-pipe smoking in Iran. 
Authors’ Contribution
All authors of this research paper have directly participated in 
the planning, execution, or analysis of the study. MH, HR, MM, 
MGH, EM, EE, AAH, AR, AR, ARM, PB, EW, FK, KZ, AM, FN, RS, 
AN, MS, AA, AN, RS, AS, MB, MM, EP, HP, SE, ON, SS, RS, AN 
contributed to the design and implementation of the study. KZ, FK, 
EP, as corresponding authors supervised the conduct and analyses 
of this study. All authors of this paper have read and approved 
the final version submitted. The contents of this manuscript have 
not been copyrighted or published previously. The contents of 
this manuscript are not now under consideration for publication 
elsewhere. The contents of this manuscript will not be copyrighted, 
submitted, or published elsewhere while acceptance by the journal 
is under consideration. There are no directly related manuscripts or 





























Figure 2. Numbers of Cases and Controls in the IROPICAN Study, by Gender, Age and Province.
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